IL-17 Blockade to Decrease irAEs (REPLAY)

Summary

The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.

Timeline

Start

2026-03-12

Primary completion

2027-06-30

Completion

2030-06-30

Drugs

Indications